- The first patient has been enrolled in a 60-subject Phase 2 clinical trial assessing Can-Fite BioPharma's (CANF -2.1%) Namodenoson for the treatment of nonalcoholic fatty liver disease with/without nonalcoholic steatohepatitis.
- The primary endpoints of the 12-week study are safety and the percent change from baseline in liver fat (triglyceride) concentration.
- Namodenoson, formerly CF102, is an orally available small molecule that binds to the A3 adenosine receptor. It is also being developed for second-line liver cancer.
- Previously: Can-Fite on go with mid-stage study of namodenoson in fatty liver disease (July 17)